Switching Antipsychotics Reduces Cardiovascular Risk Factors

If patients are stable on olanzapine (Zyprexa), quetiapine (Seroquel), or risperidone (Risperdal) but are experiencing adverse metabolic effects, it might make sense to switch to a medication that has a lower risk of causing such effects. But would such a switch reduce obesity and cholesterol at the risk of a relapse?

Current Subscribers

Purchase a subscription

To view the full content, you need to purchase a subscription.